舍曲林合并喹硫平治疗强迫症的随机对照研究

目的:探讨舍曲林合并喹硫平治疗强迫症的疗效和安全性。方法:86例符合国际疾病分类第10版(ICD-10)诊断标准的强迫症患者随机分为舍曲林合并喹硫平组(简称合用组,N=43)和单用舍曲林组(简称单用组,N=43),疗程8周。采用耶鲁-布朗强迫症量表(Yale-Brown Obsessive Compulsive Scale,Y-BOCS)、汉密顿焦虑量表(Hamilton Depression Scale,HAMA)评定疗效,采用治疗中需处理的不良反应症状量表(Treatment Emergent Symptoms Scale,TESS)评定安全性。结果:单用组有1例脱落而未纳入统计分析。在8周末,合用组的显效率高于单用组(72.1%vs.47.6%,P0.05);两组治疗后Y-BOCS、HAMA评分均低于治疗前如,合用组Y-BOCS评分(11.74±4.50)vs.(25.00±5.19),P0.001];两组治疗后合用组Y-BOCS、HAMA评分低于单用组如,Y-BOCS评分合用组(11.74±4.50)vs.单用组(14.38±4.18),P0.001]。两组TESS评分在治疗后第2、4、6及8周末差异均无统计学意义(均P0.05)。合用组困倦和心率过速的发生率高于单用组(37.2%vs.4.8%;27.9%vs.4.8%,P0.001或0.05),但多在2周内消失。其他常见不良反应,如,恶心、焦虑、头痛、便秘两组差异均无统计学意义(均P0.05)。结论:舍曲林合并小剂量喹硫平治疗强迫症可提高疗效,安全性较好,是一种值得借鉴的策略。

A randomized controlled trial of sertraline combining with quetiapine in treatment of obsessive-compulsive disorder

Objective:To investigate the efficacy and safety of sertraline combining with quetiapine in the treatment of obsessive-compulsive disorder(OCD).Methods:A total of 86 patients who met the criteria for OCD in International Classification of Diseases(ICD-10) were randomly assigned to two groups.One group was treated with sertraline combining with quetiapine and the other with sertraline only for 8 weeks.The efficacy was measured with the Yale-Brown Obsessive Compulsive Scale(Y-BOCS) and the Hamilton Depression...